Fusco Alessandra, Savio Vittoria, Chiaromonte Adriana, Alfano Alberto, D'Ambrosio Sergio, Cimini Donatella, Donnarumma Giovanna
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Microorganisms. 2023 Aug 31;11(9):2201. doi: 10.3390/microorganisms11092201.
Urinary tract infections (UTIs) and catheter-associated UTIs (CAUTIs) are the principal hospital-acquired infections. Between these, bacterial prostatitis is believed to be the leading cause of recurrent UTIs in men under 50 years of age and is often unresponsive to antibiotic treatment. is more commonly associated with UTIs in these abnormalities, especially in patients undergoing catheterization. spp. are an important component of the human microbiota and occur in large quantities in foods. Probiotics are proposed as an alternative to antibiotic therapy in the treatment of urinary tract infections. In addition to their ability to produce antimicrobial metabolites, they have immunomodulatory activity and do not cause side effects. For this reason, the combination of probiotic microorganisms and conventional drugs was considered. The aim of this work was to select the most active strains against two clinical isolates of on bladder and prostatic epithelium, potentially exploitable to improve the clinical management of UTIs.
尿路感染（UTIs）和导尿管相关尿路感染（CAUTIs）是主要的医院获得性感染。其中，细菌性前列腺炎被认为是50岁以下男性复发性尿路感染的主要原因，并且对抗生素治疗通常无反应。在这些异常情况中，尤其是在接受导尿术的患者中，[此处原文缺失具体内容]与尿路感染更为相关。[此处原文缺失具体内容]是人类微生物群的重要组成部分，在食物中大量存在。益生菌被提议作为治疗尿路感染的抗生素疗法的替代方法。除了具有产生抗菌代谢物的能力外，它们还具有免疫调节活性且不会引起副作用。因此，考虑了益生菌微生物与传统药物的组合。这项工作的目的是选择对两种临床分离株[此处原文缺失具体内容]在膀胱和前列腺上皮上最具活性的[此处原文缺失具体内容]菌株，有可能用于改善尿路感染的临床管理。
